1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis program provides culturally and linguistically appropriate business education and mentorship services to Hispanic residents who have recently started a business or aspire to establish a new one.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: New Jersey non-profit organizations with 501(c)(3) status that serve Hispanic residents, particularly those who have recently initiated a business or aspire to establish a new business. Confirm the full requirements in the official notice before applying.
The current listing shows $75,000 (maximum). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Hispanic Entrepreneurship Assistance Program (HEAP) is funded by Center for Hispanic Policy, Research and Development (NJ.gov). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. This is a phased initiative for early stage projects. The R61 phase provides support to identify and test initial prototype designs, to identify a disease target and generate experimental design, and to identify, test and pilot research tools. The R33 phase provides support for continued prototype development and testing, in addition to modifying design features and user feedback, diagnostic product generation, exploration of assay components, and characterization of a load design, and research tool improvement, large trial testing and data integration. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program. Funding Opportunity Number: RFA-HL-26-019. Assistance Listing: 93.233,93.837,93.838,93.839. Funding Instrument: G. Category: HL.
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational supportneeded for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program. Funding Opportunity Number: RFA-HL-26-017. Assistance Listing: 93.233,93.837,93.838,93.839,93.855. Funding Instrument: G. Category: HL.
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program. Funding Opportunity Number: RFA-HL-26-020. Assistance Listing: 93.233,93.837,93.838,93.839. Funding Instrument: G. Category: HL.
BJA posted O-BJA-2026-172778 on September 24, 2026 — $25 million, roughly 50 awards at up to $500,000, dual October 20 and October 27 deadlines. The eligibility conditions are the real story.
Read articleSimpler.Grants.gov became the default search in December 2025 and targets 35 percent of Grants.gov competitions by end of 2026, with full replacement slated for 2027. But submission still runs on legacy infrastructure and still requires SAM.gov, UEI, and AOR authorization. Here is what actually changed, what did not, and the five traps in the two-system year.
Read articleNOT-OD-26-112 released a draft NIH Biosafety Policy for Research Involving Biohazards on August 19, 2026. It would replace the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, extend IBC jurisdiction from engineered molecules to wild-type agents, toxins and prions, impose 24-hour incident reporting, and make the Biosafety Officer a federally defined role. Here is what actually changes and how to respond before the October 19, 2026 deadline.
Read article